Associated Papers
Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic Resistance.
Mcdaid H et al.
Biorxiv : the Preprint Server for Biology, 2026
A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non-small cell lung cancer (NSCLC).
Du Y et al.
Science Advances, 2026
Exon-level TP53 alterations and PD-L1 expression identified by pretreatment NGS stratify survival in EGFR-mutant non-small cell lung cancer treated with first-line osimertinib.
Kim SE et al.
Translational Lung Cancer Research, 2025
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.
Iwama E et al.
Lung Cancer (amsterdam, Netherlands), 2025
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
Anaplastic Lymphoma Kinase (ALK) Fusion as a Resistance Mechanism to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors With Complete Response After Osimertinib and Alectinib: A Case Report and Literature Review.
Cheung BMF et al.
Cureus, 2025
Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors.
Xie Y et al.
Lung Cancer (amsterdam, Netherlands), 2025
Complementary modes of resistance to EGFR TKI in lung adenocarcinoma through MAPK activation and cellular plasticity.
Zatzman M et al.
Biorxiv : the Preprint Server for Biology, 2025
Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy.
Hsu PC et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025
Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis.
Li YK et al.
Acta Pharmacologica Sinica, 2025
Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.
Vadagam P et al.
Current Oncology (toronto, Ont.), 2025
Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Kim S et al.
Iscience, 2025
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
Popat S et al.
British Journal of Cancer, 2025
Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.
Myall NJ et al.
Jto Clinical and Research Reports, 2025
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma.
Sun D et al.
Experimental Hematology & Oncology, 2025
KEAP1-NRF2 Pathway as a Novel Therapeutic Target for EGFR-Mutant Non-small Cell Lung Cancer.
Choi JS et al.
Tuberculosis and Respiratory Diseases, 2025
Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations.
Wang M et al.
Lung Cancer (amsterdam, Netherlands), 2025
Advanced lung adenocarcinoma harboring uncommon EGFR 19 Del and T790M/trans-C797S mutations after resistance: a case report and literature review.
Xiao Y et al.
Frontiers in Oncology, 2025
Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature.
Resuli B et al.
Frontiers in Oncology, 2025
Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance.
Mo Z et al.
Frontiers in Immunology, 2025
Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations.
Yang X et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2024
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study.
van der Wel JWT et al.
Neuro-oncology, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
van der Wel JWT et al.
Lung Cancer (amsterdam, Netherlands), 2024
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations.
Thomas BJ et al.
Npj Precision Oncology, 2024
Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient.
Pons-Tostivint E et al.
Respiratory Medicine and Research, 2024
Brigatinib combined with cetuximab in the fifth-line treatment of non-small cell lung cancer with EGFR p.C797S mutation in critically ill patients: a report of two cases and literature review.
Liu J et al.
Anti-cancer Drugs, 2024
Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.
Lee PH et al.
International Journal of Molecular Sciences, 2024
A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation.
Trinh JQ et al.
Oncology (williston Park, N.y.), 2024
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.
de Jager VD et al.
Npj Precision Oncology, 2024
A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
Wu H et al.
Cancer Medicine, 2024
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
Lu C et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
Valproic acid increased the efficacy of EGFR TKIs on EGFR/TP53 co-mutated lung cancers and downregulated mutant-p53 levels.
Hu M et al.
Molecular Carcinogenesis, 2024
Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations.
Ding W et al.
Respiratory Research, 2024
Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G et al.
Pathology Oncology Research : Por, 2024
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.
Sanchis-Borja M et al.
Oncotargets and Therapy, 2024
Splice-Switching Antisense Oligonucleotides Targeting Extra- and Intracellular Domains of Epidermal Growth Factor Receptor in Cancer Cells.
Balachandran AA et al.
Biomedicines, 2023
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Hara N et al.
Translational Lung Cancer Research, 2023
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.
Maeda C et al.
Thoracic Cancer, 2023
Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report.
Falk M et al.
Current Oncology (toronto, Ont.), 2023
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.
Jóri B et al.
Current Oncology (toronto, Ont.), 2023
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib.
Yang LL et al.
Translational Cancer Research, 2023
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C et al.
Pharmaceutics, 2023
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer.
Li S et al.
Cancers, 2023
Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
Chiang CL et al.
Thoracic Cancer, 2023
Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations.
Osoegawa A et al.
Investigational New Drugs, 2023
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.
Nishimura T et al.
Thoracic Cancer, 2023
Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC.
Kobayashi K et al.
International Journal of Molecular Sciences, 2023
Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib.
Kian W et al.
Frontiers in Oncology, 2023
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2022